Protein-glycan interactions as targets of intravenous/subcutaneous immunoglobulin (IVIg/SCIg) preparations

Benzer Materyaller

• Streptococcus pneumoniae antibody titres in patients with primary antibody deficiency receiving intravenous immunoglobulin (IVIG) compared to subcutaneous immunoglobulin (SCIG)
  Yazar:: Knutsen, A P, ve diğerleri
  Baskı/Yayın Bilgisi: (2015)
• Intravenous Immunoglobulins: Evolution of Commercial IVIG Preparations
  Yazar:: Hooper, John A.
  Baskı/Yayın Bilgisi: (2008)
• Implications to payers of switch from hospital-based intravenous immunoglobulin (IVIg) to home-based subcutaneous immunoglobulin (SCIg) therapy in patients with primary immunodeficiencies (PID) and secondary immunodeficiencies (SID) in Canada
  Yazar:: Gerth, William C, ve diğerleri
  Baskı/Yayın Bilgisi: (2014)
• Rational use of immunoglobulins (IVIgs and SCIgs) in secondary antibody deficiencies
  Yazar:: Jeroen S. Goede, ve diğerleri
  Baskı/Yayın Bilgisi: (2024-09-01)
• Human intravenous immunoglobulin (IVIG) preparations degranulate human neutrophils in vitro
  Yazar:: Teeling, J L, ve diğerleri
  Baskı/Yayın Bilgisi: (1998)